A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06618287

Public ClinicalTrials.gov record NCT06618287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Study identification

NCT ID: NCT06618287
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 416 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 3, 2025
Primary completion: Feb 25, 2031
Completion: Feb 25, 2031
Last update posted: Aug 17, 2026

2025 – 2031

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center	Miami	Florida	33136	Recruiting
Local Institution - 0065	Iowa City	Iowa	52242	Not yet recruiting
Local Institution - 0140	St Louis	Missouri	63110	Not yet recruiting
John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
Local Institution - 0102	Columbus	Ohio	43212	Not yet recruiting
Providence Portland Medical Center	Portland	Oregon	97213	Recruiting
Providence St. Vincent Medical Center	Portland	Oregon	97225	Recruiting
Local Institution - 0052	Portland	Oregon	97239	Not yet recruiting
Local Institution - 0014	Pittsburgh	Pennsylvania	15232	Withdrawn
University of Tennessee Medical Center	Knoxville	Tennessee	37920	Recruiting
NEXT Oncology - Irving	Irving	Texas	75039	Recruiting
Swedish Medical Center	Seattle	Washington	98104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06618287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 17, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06618287 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →